DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000014626
- Lead Sponsor
- gifu university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
Regardless of the adjuvant therapy, (tegafur, gimeracil, Oterashiru component of cases TS-capsule with a history of severe hypersensitivity to the 80-containing formulations polysorbate cases and docetaxel there is a treatment history TS-capsule, docetaxel, nedaplatin patients with a history of severe hypersensitivity to the formulation containing platinum or other cases nedaplatin with a history of severe hypersensitivity to the potassium) Cases of disease-free period with active double cancer of less than 5 years Cases (intestinal paralysis, intestinal obstruction, interstitial pneumonia, lung fibrosis, it is difficult to control diabetes, etc.) have a serious complication Cases with active infection Patients with edema requiring treatment Pleural effusion requiring treatment, patients with ascites Patients with a wide range of bone metastases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Study of efficacy and safety and the setting of optimal capacity
- Secondary Outcome Measures
Name Time Method